For Immediate Release
Media Contact: Kriss Bivens Cloyd
Date: June 4, 2014
Idaho Reaches Settlement with GlaxoSmithKline
(Boise) – Pharmaceutical company GlaxoSmithKline, LLC (GSK) will pay the State more than $1.3 million as part of a $105 million multistate settlement, Attorney General Lawrence Wasden said. The settlement with GSK resolves allegations that the company unlawfully promoted its asthma drug, Advair®, as well as antidepressant drugs Paxil® and Wellbutrin®. Wasden joined 44 other states in the settlement. Wasden's lawsuit alleged the company violated the Idaho Consumer Protection Act by misrepresenting the uses and qualities of the drugs.
"Idahoans relied on the advertising claims made by this company and expected the company to tell the truth about the proper use and advantages of taking the drug," Attorney General Wasden said.
The Consent Judgment also requires GSK to reform its marketing and promotional practices. Specifically, GSK shall not:
The Consent Judgment also requires GSK to continue its Patient First Program through March 2019. The Patient First Program reduces financial incentives for sales representatives to engage in deceptive marketing. In addition, the Judgment requires scientifically-trained personnel to be ultimately responsible for developing and approving responses to healthcare provider questions and for these responses to be unbiased and non-promotional.
- End -